LabCorp Announces 2019 Fourth Quarter and Full Year Results and Provides 2020 Guidance

Revenue: Q4 of $3.0 billion , up 6% over 2018; Full year of $11.6 billion , up 2% over 2018 Diluted EPS: Q4 of $2.32 , up from $1.56 last year; Full year of $8.35 , down from $8.61 last year Adjusted EPS: Q4 of $2.86 , up 13% over 2018; Full year of $11.32 , up 3% over 2018 Free Cash Flow: Q4 of

LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s Annual Scorecard on LGBTQ Workplace Equality

Receives Designation as a Best Place to Work for LGBTQ Equality For Third Consecutive Year BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 21, 2020-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect

LabCorp to Adopt Thermo Fisher Scientific’s Ion Torrent Genexus Next-Generation Sequencing System and Pan-Cancer Assay for Use in Oncology Research and Development

BURLINGTON, N.C. & CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 14, 2020-- LabCorp® (NYSE: LH) announced it will adopt the Ion Torrent Genexus System* and Oncomine Precision Assay* for use in research and development of companion diagnostics as well as other future oncology and precision medicine

LabCorp to Announce Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 13, 2020-- LabCorp® (NYSE: LH) will release its fourth quarter and full year 2019 financial results before the market opens on Thursday, Feb. 13, 2020 , and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.